Evidence map›Paper›PMID 41912087›Full record

ArticleJournal of hepatology2026

Global patterns of mutational profiles in biliary tract cancer.

Yan Zhu, Jason A Wu, Dengyong Zhang, Saikat Chowdhury, Huamin Wang, Sunyoung S Lee, Funda Meric-Bernstam, Zishuo I Hu, Milind Javle, Lawrence N Kwong

Abstract read
In one paragraph

Article in Journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan ZhuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Jason A WuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Dengyong ZhangDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Saikat ChowdhuryDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Huamin WangDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Sunyoung S LeeDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Zishuo I HuDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Milind JavleDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Lawrence N KwongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. Electronic address: lkwong@mdanderson.org.

Funding

Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance MutationsR01HG011356 · NHGRI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWONG, LAWRENCE, VEISEH, OMID · 2020 to 2023
$2.7M
A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways SimultaneouslyR01CA251608 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWONG, LAWRENCE · 2020 to 2024
$2.5M
NCI NIH HHS R01 CA251608NHGRI NIH HHS R01 HG011356
6 · The paper itself

Abstract

BACKGROUND &

aimsBiliary tract cancers (BTCs) are a group of rare but highly lethal malignancies that include intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and gallbladder carcinoma (GBC). A major challenge in modeling and treating these cancers is their highly heterogeneous mutational landscapes, both within and across subtypes, as well as across geographic and etiological contexts. This heterogeneity necessitates large cohorts to enable robust statistical analyses. Here, we collate and analyze data from more than 30 next-generation sequencing studies to provide a comprehensive overview of BTC mutational patterns and their potential clinical implications.

methodsMutation data from 5,123 BTC samples from 13 countries were standardized, focusing on a set of 29 bona fide oncogenes and tumor suppressor genes. We performed statistical analyses to evaluate hypotheses related to mutation prevalence, etiology, co-mutation patterns, and recurrent mutations.

resultsThis analysis provides robust estimates of mutation prevalence across geographic regions, BTC subtypes, and hepatitis status, highlighting genes whose alteration frequencies vary by anatomical location and etiology. or example, iCCA in Eastern vs. Western hemispheres showed large differences in alteration prevalence for FGFR2, IDH1, KRAS, TP53, CDKN2A, and BAP1, whereas eCCA and GBC exhibited only modest hemispheric differences. We further show that these differences, as well as those observed between iCCA and eCCA, are partly explained by variation in the mutation profiles and prevalences of small- vs. large-duct subtypes. The large sample size also enabled systematic characterization of gene-gene co-occurrence and mutual exclusivity across BTC subtypes, along with a clinically oriented catalogue of recurrent mutations in oncogenes and tumor suppressor genes.

conclusionThis integrative cross-study analysis provides a global view of BTC genomics, clarifying how geography, etiology, and anatomical subtype collectively shape driver mutation landscapes. IMPACT AND IMPLICATIONS: Our results provide statistical depth, uncover new mutational relationships, and suggest high-priority avenues for basic and translational research in biliary tract cancer. By integrating data across diverse geographic and etiological contexts, this study highlights how mutation prevalence and co-mutation patterns vary systematically with anatomical subtype, hepatitis status, and region. These findings offer a more nuanced framework for interpreting BTC genomics and underscore the importance of stratified approaches to research and treatment. Collectively, this work establishes a robust foundation for future biological studies, biomarker development, and the design of clinical trials that are tailored to geographic origin, underlying etiology, and specific mutational and co-mutation landscapes, ultimately supporting more precise and effective therapeutic strategies in BTC.

Indexed as

Bile Duct NeoplasmsBiliary Tract NeoplasmsCholangiocarcinomaGallbladder NeoplasmsMutationDNA Mutational AnalysisHigh-Throughput Nucleotide SequencingHumansBiliary tract cancercholangiocarcinomagallbladder cancermutation

Identifiers

PMID41912087
PMCPMC13662757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.